Wang Chunyang, Yu Liang, Hu Fengchun, Wang Juan, Chen Xijuan, Tai Shanshan, Cheng Bin
Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong 510055, P.R. China.
Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
Oncol Lett. 2017 Oct;14(4):4527-4534. doi: 10.3892/ol.2017.6780. Epub 2017 Aug 21.
Proline rich 11 (PRR11) serves an important role in the development and progression of a number of types of human cancer. However, the clinical role of PRR11 in tongue squamous cell carcinoma (TSCC) remains unknown. The present study aimed to investigate the expression and clinicopathological significance of PRR11 in TSCC. The Cancer Genome Atlas analysis demonstrated that the upregulation of PRR11 in TSCC correlated with poor prognosis. The data of the present study revealed that PRR11 mRNA and protein expression was markedly upregulated in human TSCC tissues. Immunohistochemistry on 72 archived paraffin-embedded TSCC specimens suggested that high levels of PRR11 expression were significantly associated with clinical stage (P<0.001), T classification (P=0.009), N classification (P=0.017) and vital status (P=0.010). In addition, patients with TSCC with higher PRR11 expression exhibited substantially shorter survival times compared with patients with lower PRR11 expression (P<0.001). Univariate and multivariate analyses indicated that PRR11 upregulation may be an independent prognostic factor for patients with TSCC (P=0.001). Taken together, and to the best of our knowledge, the results of the present study demonstrated for the first time that PRR11 is involved in the development and progression of TSCC, and may serve as a useful prognostic marker and an effective target for treating TSCC.
富含脯氨酸11（PRR11）在多种人类癌症的发生和发展中起重要作用。然而，PRR11在舌鳞状细胞癌（TSCC）中的临床作用仍不清楚。本研究旨在探讨PRR11在TSCC中的表达及其临床病理意义。癌症基因组图谱分析表明，TSCC中PRR11的上调与预后不良相关。本研究数据显示，PRR11 mRNA和蛋白表达在人TSCC组织中明显上调。对72份存档石蜡包埋TSCC标本进行的免疫组织化学分析表明，PRR11高表达与临床分期（P<0.001）、T分级（P=0.009）、N分级（P=0.017）及生存状态（P=0.010）显著相关。此外，与PRR11低表达患者相比，PRR11高表达的TSCC患者生存时间显著缩短（P<0.001）。单因素和多因素分析表明，PRR11上调可能是TSCC患者的独立预后因素（P=0.001）。综上所述，据我们所知，本研究结果首次证明PRR11参与TSCC的发生和发展，并可能作为一种有用的预后标志物及治疗TSCC的有效靶点。
